These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20965954)

  • 21. Hyaline-vascular type of Castleman's disease (angiofollicular lymph node hyperplasia) with monotypic plasma cells. An immunohistochemical study with monoclonal antibodies.
    Chilosi M; Menestrina F; Lestani M; Bonetti F; Scarpa A; Caligaris-Cappio F; Pizzolo G; Perini A; Fiore-Donati L
    Histol Histopathol; 1987 Jan; 2(1):49-55. PubMed ID: 2980702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases.
    Zarate-Osorno A; Medeiros LJ; Danon AD; Neiman RS
    Arch Pathol Lab Med; 1994 Mar; 118(3):270-4. PubMed ID: 8135630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Castleman's disease, intermediate type: a case report.
    Raphael V; Lyngdoh RH
    Indian J Pathol Microbiol; 2006 Oct; 49(4):603-4. PubMed ID: 17183872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of plasma cell type of Castleman's disease and IgG4-related sclerosing disease: a histopathological and immunohistochemical study.
    Jo JH; Park YS; Jeon YK; Nam SJ; Huh J
    Pathobiology; 2011; 78(4):227-32. PubMed ID: 21778790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.
    Ide M; Kawachi Y; Izumi Y; Kasagi K; Ogino T
    Eur J Haematol; 2006 Feb; 76(2):119-23. PubMed ID: 16405432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD56-Positive cutaneous lymphoma with multicentric Castleman's disease-like systemic manifestations.
    Amo Y; Ogata F; Okabe S; Yonemoto K; Katsuoka K
    J Dermatol; 2001 Dec; 28(12):746-52. PubMed ID: 11804073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiofollicular lymph node hyperplasia resembling a spinal nerve sheath tumor: a rare case of Castleman's disease.
    Stevens EA; Strowd RE; Mott RT; Oaks TE; Wilson JA
    Spine J; 2009 Sep; 9(9):e18-22. PubMed ID: 19482516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extralymphonodal Castleman's disease. A case report.
    Malaguarnera M; Restuccia N; Laurino A; Lo Manto PC; Vinci E; Pistone G
    Panminerva Med; 1999 Dec; 41(4):363-6. PubMed ID: 10705721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia: a report of 16 cases.
    Kojima M; Nakamura S; Shimizu K; Itoh H; Yamane Y; Murayama K; Tanaka H; Sugihara S; Shimano S; Sakata N; Masawa N
    Int J Surg Pathol; 2004 Jan; 12(1):25-30. PubMed ID: 14765269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical characteristics of 5 children with Castleman's disease and review of literature].
    Huang S; Zhou CJ; Jin M; Jin L; Zhang R; Zhang YH
    Zhonghua Er Ke Za Zhi; 2010 Aug; 48(8):625-8. PubMed ID: 21055311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitor of differentiation 1 is a candidate prognostic marker in multicentric Castleman's disease.
    Liu C; Liu YR; Chen J; Zhuo SY; Dalin M; Liu SH; Wei FC
    Ann Hematol; 2014 Jul; 93(7):1177-83. PubMed ID: 24599583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical features and prognosis in 49 patients with Castleman's disease].
    Yu GP; Wang SJ; Shi J; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):570-4. PubMed ID: 19968073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of interleukin-6 and its clinicopathological significance in Castleman's disease].
    Lai YM; Li M; Liu CL; Huang X; Yu GH; Wang XY; Sun L; Chen J; Gao ZF
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):404-8. PubMed ID: 23688750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Multicentric Castleman's disease accompanied with both lymphoid interstitial pneumonia and interstitial nephritis].
    Sato T; Wakabayashi Y; Hirasawa A; Tashiro Y; Nishikawa T; Chiba S
    Rinsho Ketsueki; 1994 Nov; 35(11):1322-8. PubMed ID: 7823399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor.
    Zhang L; Li Z; Cao X; Feng J; Zhong D; Wang S; Zhou D; Li J
    Sci Rep; 2016 Mar; 6():23831. PubMed ID: 27029894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.
    Otani K; Inoue D; Fujikura K; Komori T; Abe-Suzuki S; Tajiri T; Itoh T; Zen Y
    Oncotarget; 2018 Jan; 9(6):6691-6706. PubMed ID: 29467920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012).
    Kawabata H; Takai K; Kojima M; Nakamura N; Aoki S; Nakamura S; Kinoshita T; Masaki Y
    J Clin Exp Hematop; 2013; 53(1):57-61. PubMed ID: 23801135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: A rare case report and review of the literature.
    Allegra A; Rotondo F; Russo S; Calabrò L; Maisano V; Bacci F; Musolino C
    Blood Cells Mol Dis; 2015 Oct; 55(3):206-7. PubMed ID: 26227845
    [No Abstract]   [Full Text] [Related]  

  • 39. TAFRO syndrome: 2 cases and review of the literature.
    Kawashima M; Usui T; Okada H; Mori I; Yamauchi M; Ikeda T; Kajita K; Kito Y; Miyazaki T; Fujioka K; Ishizuka T; Morita H
    Mod Rheumatol; 2017 Nov; 27(6):1093-1097. PubMed ID: 26052800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
    Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.